Cash, cash equivalents and marketable securities were $588.9 million as of September 30, 2025, compared to $621.2 million as of June 30, 2025. In October, Apogee completed a $345 million underwritten public equity offering resulting in $913 million cash, cash equivalents and marketable securities on a pro forma basis as of September 30, 2025. Based on current operating plans, Apogee expects its existing total cash will enable the company to fund its operating expenses into the second half of 2028.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $70 from $60 at RBC Capital
- Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy
- Apogee Therapeutics initiated with a Buy at Craig-Hallum
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know